Matches in Nanopublications for { ?s ?p "[Novel PLK, CENPE, and AURKB inhibitors should be assessed for therapeutic utility in poor prognosis cyclin B1-overexpressing breast cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 7 of
7
with 100 items per page.
- NP311652.RAv-y2Wg5Gbyr5Obyu1ScpCnDbD5Dy43AiQ_3OW-fi4nQ130_assertion description "[Novel PLK, CENPE, and AURKB inhibitors should be assessed for therapeutic utility in poor prognosis cyclin B1-overexpressing breast cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP311652.RAv-y2Wg5Gbyr5Obyu1ScpCnDbD5Dy43AiQ_3OW-fi4nQ130_provenance.
- NP520426.RAjRHTy-0dfafpNWuVntbXCngzPdEDJUpz7ecRg7mE3oE130_assertion description "[Novel PLK, CENPE, and AURKB inhibitors should be assessed for therapeutic utility in poor prognosis cyclin B1-overexpressing breast cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP520426.RAjRHTy-0dfafpNWuVntbXCngzPdEDJUpz7ecRg7mE3oE130_provenance.
- NP795376.RAm_Sa68Kev_RirqkZ4BIb2e1VKN0DAo6hdMCko6l9T7c130_assertion description "[Novel PLK, CENPE, and AURKB inhibitors should be assessed for therapeutic utility in poor prognosis cyclin B1-overexpressing breast cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP795376.RAm_Sa68Kev_RirqkZ4BIb2e1VKN0DAo6hdMCko6l9T7c130_provenance.
- NP860091.RA0AA7a0SPYibjH2rClN12rqDeQVsqMtFQPAhY_mB0-Pw130_assertion description "[Novel PLK, CENPE, and AURKB inhibitors should be assessed for therapeutic utility in poor prognosis cyclin B1-overexpressing breast cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP860091.RA0AA7a0SPYibjH2rClN12rqDeQVsqMtFQPAhY_mB0-Pw130_provenance.
- NP817637.RAZCM6haWkF8E-Sy4-tQd2EPR5dgFQLCn7n0o2Ks5d1IM130_assertion description "[Novel PLK, CENPE, and AURKB inhibitors should be assessed for therapeutic utility in poor prognosis cyclin B1-overexpressing breast cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP817637.RAZCM6haWkF8E-Sy4-tQd2EPR5dgFQLCn7n0o2Ks5d1IM130_provenance.
- NP741062.RASUVeHdDAqDpT77YIOYjDX3GQECfS8RSHpkm6ufujmdI130_assertion description "[Novel PLK, CENPE, and AURKB inhibitors should be assessed for therapeutic utility in poor prognosis cyclin B1-overexpressing breast cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP741062.RASUVeHdDAqDpT77YIOYjDX3GQECfS8RSHpkm6ufujmdI130_provenance.
- assertion description "[Novel PLK, CENPE, and AURKB inhibitors should be assessed for therapeutic utility in poor prognosis cyclin B1-overexpressing breast cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.